We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+5.45%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$3.11B
AUM Growth
+$2.21M
Cap. Flow
-$39.8M
Cap. Flow %
-1.28%
Top 10 Hldgs %
35.29%
Holding
188
New
16
Increased
26
Reduced
40
Closed
17

Top Buys

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$35.7M
2
SGEN
Seagen Inc. Common Stock
SGEN
+$32.2M
3
MRNA icon
Moderna
MRNA
+$25.5M
4
DHR icon
Danaher
DHR
+$16.7M
5
RMD icon
ResMed
RMD
+$15.7M

Top Sells

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$25.3M
2
EXAS
Exact Sciences
EXAS
+$21.5M
3
CTLT
CATALENT, INC.
CTLT
+$19.2M
4
XRAY icon
Dentsply Sirona
XRAY
+$17.1M
5
CI icon
Cigna
CI
+$16.6M

Sector Composition

Rank Sector Weight
1 Healthcare 96.33%
2 Real Estate 2.82%
3 Industrials 0.17%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
UNH icon
1
UnitedHealth
UNH
$383B
$161M 5.18%
320,354
+14,225
+5% +$6.44M
MRNA icon
2
Moderna
MRNA
$23B
$139M 4.47%
546,624
+87,168
+19% +$25.5M
AMGN icon
3
Amgen
AMGN
$209B
$129M 4.16%
574,918
– –
GILD icon
4
Gilead Sciences
GILD
$163B
$122M 3.94%
1,686,565
-21,500
-1% -$1.48M
TMO icon
5
Thermo Fisher Scientific
TMO
$214B
$102M 3.27%
152,326
+6,210
+4% +$3.88M
HZNP
6
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$96.7M 3.11%
897,540
-12,800
-1% -$1.4M
REGN icon
7
Regeneron Pharmaceuticals
REGN
$77.4B
$90.3M 2.91%
143,049
-4,966
-3% -$3.05M
JNJ icon
8
Johnson & Johnson
JNJ
$617B
$88.4M 2.84%
516,652
– –
ILMN icon
9
Illumina
ILMN
$31B
$86.1M 2.77%
232,546
+33,152
+17% +$12.6M
ABT icon
10
Abbott
ABT
$183B
$82.1M 2.64%
583,277
-73,761
-11% -$9.44M
PFE icon
11
Pfizer
PFE
$142B
$69.2M 2.23%
1,171,903
+721,524
+160% +$35.7M
ABBV icon
12
AbbVie
ABBV
$455B
$69M 2.22%
509,817
-14,396
-3% -$1.7M
DHR icon
13
Danaher
DHR
$138B
$66.6M 2.14%
228,262
+60,548
+36% +$16.7M
LLY icon
14
Eli Lilly
LLY
$1.03T
$63.6M 2.05%
230,432
-45,000
-16% -$11.4M
SGEN
15
DELISTED
Seagen Inc. Common Stock
SGEN
$61.8M 1.99%
399,527
+192,193
+93% +$32.2M
MRK icon
16
Merck
MRK
$321B
$60.4M 1.94%
788,122
-28,183
-3% -$2.24M
VRTX icon
17
Vertex Pharmaceuticals
VRTX
$122B
$60M 1.93%
273,046
– –
IDXX icon
18
Idexx Laboratories
IDXX
$44.1B
$52.5M 1.69%
79,663
– –
MDT icon
19
Medtronic
MDT
$110B
$52.3M 1.68%
505,860
-94,862
-16% -$11M
SYK icon
20
Stryker
SYK
$133B
$49.1M 1.58%
183,582
+33,082
+22% +$8.68M
MCK icon
21
McKesson
MCK
$101B
$46.9M 1.51%
188,522
+6,945
+4% +$1.52M
BMY icon
22
Bristol-Myers Squibb
BMY
$132B
$46.6M 1.5%
747,043
+134,807
+22% +$7.91M
AZN icon
23
AstraZeneca
AZN
$266B
$45.9M 1.48%
393,743
-12,721
-3% -$1.5M
SYNH
24
DELISTED
Syneos Health, Inc. Class A Common Stock
SYNH
$41.4M 1.33%
403,087
+159,454
+65% +$15.3M
GH icon
25
Guardant Health
GH
$20.2B
$35.2M 1.13%
351,484
-36,500
-9% -$3.78M
1
2 3 4 5

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q4 2021 Portfolio in Review

As of Q4 2021, Tekla Capital Management held 188 positions worth $3.11B, up 0.07% from $3.11B the previous quarter. Its ten largest holdings account for 35% of the portfolio.

Tekla Capital Management's Q4 2021 filing shows 16 new, 26 increased, 40 reduced and 17 closed positions. Its largest new stake was AMN Healthcare: 61,201 shares worth $7.49M. The largest sale was Biogen, an estimated $25.3M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 97% a quarter earlier, followed by Real Estate and Industrials.

  • Tekla Capital Management's largest Q4 2021 buy was AMN Healthcare: 61,201 shares worth $7.49M.
  • Tekla Capital Management added most to Pfizer in Q4 2021, an estimated $35.7M increase.
  • Tekla Capital Management's biggest Q4 2021 reduction was Biogen, cutting an estimated $25.3M.
  • Tekla Capital Management fully exited Exact Sciences in Q4 2021, selling an estimated $21.5M.
  • Tekla Capital Management's ten largest holdings make up 35% of its $3.11B portfolio in Q4 2021.
  • Tekla Capital Management opened 16 new positions and closed 17 in Q4 2021.
  • Tekla Capital Management's portfolio value rose 0.07% quarter-over-quarter to $3.11B.

Based on Tekla Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.